This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Analgesic nephropathy

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

This is a common cause of chronic renal failure in Europe. It is the result of chronic high intake of simple analgesics over a period of several years.

The nephropathy is characterised by chronic tubulo- interstitial nephritis and renal papillary necrosis.

Non-steroidal anti-inflammatory drugs (NSAIDs) are the most frequent cause of drug induced renal damage in clinical practice (1).

Analgesic nephropathy is much more common in women than in men (2). Typically analgesic nephropathy results in chronic renal failure in late middle age.

Analgesic nephropathy is associated with an increased incidence of urothelial maligancy (1,2,3,4).

Notes (4):

  • chronic analgesic nephropathy, particularly chronic interstitial nephritis and renal papillary necrosis, results from daily use for many years of mixtures containing at least two analgesics and caffeine or dependence-inducing drugs
  • computed tomography scan can accurately diagnose this disease even in the absence of reliable information on previous analgesic use
  • occasional to moderate regular use of aspirin and nonsteroidal anti-inflammatory drugs is without renal risk when renal function is normal
  • paracetamol use is less clear although the risk is not great.
  • continued use of non-phenacetin-combined analgesics with or without nonsteroidal anti-inflammatory drugs is associated with faster progression toward renal impairment.

Reference:


Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.